Macleods Pharmaceuticals Limited remembers many losartan-potassium / hydrochlorothiazide combination tablets because they may contain a carcinogenic substance.
According to the
Website of the US Food and Drug Administration,
the tablets, with which hypertension and hypertensive patients are treated
left ventricular hypertrophy
, contained small amounts of N-nitrosodiethylamine (NDEA).
The 100 mg / 25 mg tablets that are recalled include:
|NDC||Manufacturer||Product description||Lot / Batch||expiration date|
|33342-0052-10||Macleods Pharmaceuticals Limited||Losartan Potassium / Hydrochlorothiazide combination tablets 100 mg / 25 mg, 90 count bottles||BLM715A||Jul-2019|
"Patients using Losartan Potassium / Hydrochlorothiazide combination tablets should continue to take USP as the risk of damage to the patient's health may be greater if treatment is stopped immediately without alternative treatment," the FDA explains.
Anyone who has general questions about the return of this product should contact Qualanex via e-mail
or call 888-280-2042, 7 am to 4 pm, CST, from Monday to Friday.
To read the full release,